STOK - Stoke Therapeutics, Inc.
Chart Events
Relative Strength Index (RSI)
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 12.69 |
| Open | 12.71 |
| Bid | 12.07 x 800 |
| Ask | 12.09 x 800 |
| Day's Range | 12.05 - 12.71 |
| 52 Week Range | 6.88 - 22.87 |
| Volume | |
| Avg. Volume | 223,915 |
| Market Cap | 532.692M |
| Beta (5Y Monthly) | 0.41 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.89 |
| Earnings Date | Aug 07, 2023 - Aug 11, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 25.57 |
Fair Value
Related Research
ZacksHow Much Upside is Left in Stoke Therapeutics, Inc. (STOK)? Wall Street Analysts Think 102.91%
The consensus price target hints at a 102.9% upside potential for Stoke Therapeutics, Inc. (STOK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Simply Wall St.New Forecasts: Here's What Analysts Think The Future Holds For Stoke Therapeutics, Inc. (NASDAQ:STOK)
Stoke Therapeutics, Inc. ( NASDAQ:STOK ) shareholders will have a reason to smile today, with the analysts making...
- Simply Wall St.
Earnings Update: Stoke Therapeutics, Inc. (NASDAQ:STOK) Just Reported And Analysts Are Boosting Their Estimates
Stoke Therapeutics, Inc. ( NASDAQ:STOK ) defied analyst predictions to release its first-quarter results, which were...
ZacksAnalysts Estimate Synlogic, Inc. (SYBX) to Report a Decline in Earnings: What to Look Out for
Synlogic, Inc. (SYBX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZacksStoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates
Stoke Therapeutics, Inc. (STOK) delivered earnings and revenue surprises of 24.29% and 44.44%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Business WireStoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates
BEDFORD, Mass., May 04, 2023--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today reported financial results for the first quarter of 2023 and provided business updates including those related to STK-001, the company’s proprietary antisense oligonucleotide (ASO) being developed by Stoke as the first potential new medicine to address the genetic cause of
Business WireStoke Therapeutics to Present at the BofA Securities Health Care Conference
BEDFORD, Mass., May 03, 2023--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the BofA Securities Health Care Conference on Thursday, May 11, 2023, at 11:00 a.m. ET. (8:00 a.m. PT)
ZacksStoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: Should You Buy?
Stoke Therapeutics, Inc. (STOK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Business WireStoke Therapeutics Receives Authorization to Initiate a Phase 1/2 Study of STK-002 for Autosomal Dominant Optic Atrophy (ADOA) in the United Kingdom
BEDFORD, Mass., April 25, 2023--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced authorization of its Clinical Trial Application (CTA) by the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase 1/2 study (OSPREY) of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common
- Simply Wall St.
Investors in Stoke Therapeutics (NASDAQ:STOK) have unfortunately lost 64% over the last three years
If you love investing in stocks you're bound to buy some losers. But the last three years have been particularly tough...
Business WireStoke Therapeutics Announces That FDA Will Allow the Administration of a Higher Single Dose of STK-001 (70mg) in the Ongoing Phase 1/2a MONARCH Study of Children and Adolescents with Dravet Syndrome
BEDFORD, Mass., March 15, 2023--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that the FDA will allow the administration of a higher single dose of STK-001 (70mg) in its ongoing Phase 1/2a MONARCH study of children and adolescents with Dravet syndrome. This new 70mg single dose cohort in MONARCH will complement the ongoing evaluation of m
ZacksStoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Tops Revenue Estimates
Stoke Therapeutics, Inc. (STOK) delivered earnings and revenue surprises of 9.72% and 11.42%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Business WireStoke Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
BEDFORD, Mass., March 06, 2023--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today reported financial results for the full year ended December 31, 2022 and provided business updates.
Business WireStoke Therapeutics to Participate at Upcoming March Investor Conferences
BEDFORD, Mass., February 27, 2023--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will be participating at the following upcoming investor conferences:
- Business Wire
Stoke Therapeutics to Present at the SVB Securities Global Biopharma Conference
BEDFORD, Mass., February 07, 2023--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the virtual SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023, at 4:20 p.m. ET.
- Simply Wall St.
Companies Like Stoke Therapeutics (NASDAQ:STOK) Can Afford To Invest In Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Business WireStoke Therapeutics Highlights Strategic Priorities and Anticipated Milestones for 2023
BEDFORD, Mass., January 09, 2023--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today outlined its expected milestones and the following strategic priorities for 2023:
Business WireStoke Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
BEDFORD, Mass., January 04, 2023--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 2:15 p.m. ET (11:15 a.m. PT).
Business WireStoke Therapeutics Presents Data from a Combined Interim Analysis of the Phase 1/2a MONARCH and ADMIRAL Studies of STK-001 in Children and Adolescents with Dravet Syndrome at the American Epilepsy Society (AES) 2022 Annual Meeting
BEDFORD, Mass., December 02, 2022--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced highlights from presentations related to the ongoing clinical development of STK-001, the first potential new medicine to treat the underlying cause of Dravet syndrome. A total of seven posters will be presented at the American Epilepsy Society (AES) 2022 Ann
Business WireStoke Therapeutics to Present Data from the Company’s Dravet Syndrome Program at the American Epilepsy Society 2022 Annual Meeting
BEDFORD, Mass., November 29, 2022--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that seven abstracts related to the Company’s work in Dravet syndrome have been accepted for presentation at the American Epilepsy Society (AES) 2022 Annual Meeting, taking place December 2 – 6, in Nashville, Tennessee. The company is advancing STK-001 as pot
BenzingaStoke Therapeutics Stock Falls Post Early Efficacy Data From Lead Dravet Syndrome Program
Stoke Therapeutics Inc (NASDAQ: STOK) announced data from a planned interim analysis of the ongoing Phase 1/2a MONARCH and ADMIRAL clinical studies of STK-001 in children and adolescents with Dravet syndrome. Today's results come almost a year after Stoke touted its first-in-human data for STK-001. In addition to positive safety, pharmacokinetic (PK) and cerebrospinal fluid (CSF) exposure data, median reductions in seizure frequency were observed among patients who were treated with multiple dos
ZacksStoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Tops Revenue Estimates
Stoke Therapeutics, Inc. (STOK) delivered earnings and revenue surprises of 4.35% and 2.07%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Business WireStoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates
BEDFORD, Mass., November 14, 2022--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today reported financial results for the third quarter of 2022 and provided business updates, including positive data from a planned interim analysis of the ongoing Phase 1/2a MONARCH and ADMIRAL clinical studies of STK-001 in children and adolescents with Dravet syndrome. I
ZacksIs a Surprise Coming for Stoke Therapeutics (STOK) This Earnings Season?
Stoke Therapeutics (STOK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Business WireStoke Therapeutics to Host Webinar and Conference Call to Present Interim Data from the Phase 1/2a Studies of STK-001 in Children and Adolescents with Dravet Syndrome
BEDFORD, Mass., November 10, 2022--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will hold a webinar and conference call for analysts and investors at 8:30 a.m. Eastern Time on Monday, November 14, 2022, to present data from a planned interim analysis of the Phase 1/2a studies of STK-001 in children and adolescents with Dr